Who we are
Founded in 2012, Pond Capital, LLC is a boutique investment group focused on supporting the growth of innovative life science, medical technologies and health services companies with an emphasis on fast to market products or services that reduce the cost of delivering quality healthcare.
The managing partners of Pond Capital have been founders, board members, early stage investors, shareholders, and executives of many successful life science, medical technology companies and venture capital firms including: Tepha Medical, nContact Surgical, PneumRx, Cayenne Medical, CogENT Therapeutics, Tornier, Fabrus/Sevion, BiOWiSH Technologies, Kinsa Health, DirectDerm, Kaleo Pharma, MicroVascular Tissues, Phenolaeis, Akeso, M3DICINE, DRP Biomedical, Merck and The Vertical Group.
The unifying principle underlying Pond Capital’s investment activities remains the ability to leverage the life science, medical technology, and health service industry knowledge, experience, and network of the firm’s managing partners. This includes: direct and indirect involvement in life science and medical device operations such as corporate and business development, sales and marketing, research and development, supply chain and distribution, quality management, clinical and regulatory affairs, and transaction/portfolio management.
We approach each opportunity with a long term outlook and identify those that have superior products or services with strong management teams.
The scale of Pond Capital’s investment depends on the nature of the opportunity, with investment size up to $3,000,000 in various stages of angel and venture capital transactions. Founder-focused, Pond Capital prefers to support private investments where we can partner with the company to enhance success and value appreciation.
Kevin L. Ohashi, PhD
Kevin is a co-founding partner based in Boston, MA. Kevin serves as a Director of MicroVascular Tissues, Directerm, M3DICINE, Phenolaeis, Tauten, and HemaFlo Therapeutics.
Prior to forming Pond Capital, Kevin co-founded and is currently Managing Director of Bay Innovation Group (BIG), LLC. BIG is the founding technology development group for several early stage medical device companies that include Cayenne Medical, Inc. (Sports Medicine, Acquired by Zimmer-Biomet 2016), nContact, Inc. (Atrial Fibrillation, Acquired by Atricure 2015), and Extensia Medical, Inc. (Congestive Heart Failure). Kevin serves as CEO for Phenolaeis, a Health and Wellness Bioactive Technology Company. Kevin is a co-founder of MicroVascular Tissues (regenerative tissue), Myocardial Solutions (diagnostic imaging), Simparo (orthopaedic device), Tauten (sports technology) and Kinetxx (tele-rehabilitation).
Glen Gong, PhD
Glen G. Gong is a serial entrepreneur and investor in the healthcare, medicine and biotech space. A California native, Glen received his PH.D in Pharmaceutical Sciences from University of California at San Francisco and his Masters in Chemical Engineering from Stanford University. Glen is the co-founder of Pond Capital, a venture firm whose purpose is to build impactful new healthcare and biotech companies. Glen is driven by the desire to make a positive impact to people’s health through scaling new businesses.
Pond Capital Investments
New York, NY
Get In Touch
We’re always happy to hear from like-minded individuals who want to make the world a better place through science and technology.
We find investment referrals from someone who knows us both make the best introductions; we place a higher priority on meeting with
people referred by someone we know. We are not currently hiring and request that any inquiries about a portfolio company be made directly to the companies themselves.
For all other inquiries, please get in touch!